Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$3.62 -6.9%	$3.61	$1.75 ▼ $10.00	$246.77M	0.67	713,667 shs	1.18 million shs
IMMP Immutep	$1.83 -3.2%	$1.71	$1.32 ▼ $3.34	$267.25M	1.8	220,408 shs	104,353 shs
TSVT 2seventy bio	$5.00	$4.92	$2.29 ▼ $5.30	$266.15M	1.04	626,396 shs	N/A
ZYNE Zynerba Pharmaceuticals	$1.30	$1.30	$0.25 ▼ $1.40	$70.12M	1.32	515,333 shs	N/A

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	-3.95%	+16.64%	+30.54%	-22.82%	+84.36%
IMMP Immutep	+1.07%	-6.90%	+29.45%	-5.03%	-35.49%
TSVT 2seventy bio	0.00%	+0.20%	+0.81%	+109.21%	+11.36%
ZYNE Zynerba Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRVS Corvus Pharmaceuticals	2.349 of 5 stars	3.6	1.0	0.0	0.0	2.7	2.5	0.6
IMMP Immutep	1.8051 of 5 stars	3.5	2.0	0.0	0.0	3.9	0.0	0.0
TSVT 2seventy bio	1.1606 of 5 stars	0.9	2.0	0.0	0.0	3.9	2.5	1.3
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVS Corvus Pharmaceuticals	3.25	Buy	$16.33	351.20% Upside
IMMP Immutep	3.00	Buy	$8.50	364.48% Upside
TSVT 2seventy bio	1.80	Reduce	$4.25	-15.00% Downside
ZYNE Zynerba Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZYNE, CRVS, IMMP, and TSVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/10/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/9/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00
4/24/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/8/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
3/26/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$14.00 ➝ $15.00
3/26/2025	CRVS Corvus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/22/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
3/14/2025	TSVT 2seventy bio	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $5.00
3/11/2025	TSVT 2seventy bio	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/11/2025	TSVT 2seventy bio	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$9.00 ➝ $5.00
3/7/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.79 per share	N/A
IMMP Immutep	$5.14M	51.99	N/A	N/A	$1.05 per share	1.74
TSVT 2seventy bio	$37.86M	7.03	N/A	N/A	$5.04 per share	0.99
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	$1.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVS Corvus Pharmaceuticals	-$27.03M	-$0.98	N/A	N/A	N/A	N/A	-70.71%	-45.90%	N/A
IMMP Immutep	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
TSVT 2seventy bio	-$217.57M	-$0.10	N/A	N/A	N/A	-207.25%	-53.65%	-23.67%	5/14/2025 (Estimated)
ZYNE Zynerba Pharmaceuticals	-$35.04M	-$0.80	N/A	N/A	N/A	N/A	-90.03%	-72.62%	N/A

Latest ZYNE, CRVS, IMMP, and TSVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
5/7/2025	Q1 2025	TSVT 2seventy bio	-$0.10	$0.01	+$0.11	$0.01	$13.96 million	$22.94 million
3/25/2025	Q4 2024	CRVS Corvus Pharmaceuticals	-$0.12	-$0.18	-$0.06	-$0.18	N/A	N/A
3/25/2025	Q4 2024	TSVT 2seventy bio	-$0.23	-$0.31	-$0.08	-$0.37	$12.84 million	$2.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMMP Immutep	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVS Corvus Pharmaceuticals	N/A	0.92	0.92
IMMP Immutep	0.01	18.25	18.25
TSVT 2seventy bio	N/A	4.95	4.95
ZYNE Zynerba Pharmaceuticals	N/A	3.43	3.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVS Corvus Pharmaceuticals	46.64%
IMMP Immutep	2.32%
TSVT 2seventy bio	93.90%
ZYNE Zynerba Pharmaceuticals	11.23%

Insider Ownership

Company	Insider Ownership
CRVS Corvus Pharmaceuticals	28.50%
IMMP Immutep	3.07%
TSVT 2seventy bio	7.20%
ZYNE Zynerba Pharmaceuticals	13.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	44.15 million	Optionable
IMMP Immutep	2,021	146.04 million	141.09 million	Optionable
TSVT 2seventy bio	440	53.23 million	47.87 million	Optionable
ZYNE Zynerba Pharmaceuticals	25	53.94 million	46.91 million	Optionable

ZYNE, CRVS, IMMP, and TSVT Headlines

Recent News About These Companies

US Penny Stocks To Watch In October 2024

October 28, 2024 | uk.finance.yahoo.com

Discover 3 US Penny Stocks With Market Caps Over $70M

October 24, 2024 | uk.finance.yahoo.com

Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight

October 22, 2024 | uk.finance.yahoo.com

GW Pharma's cannabis-derived epilepsy drug approved in EU

October 7, 2024 | pharmaphorum.com

Fragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery Partners

July 31, 2024 | globenewswire.com

Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results

October 31, 2023 | finance.yahoo.com

Why Shares of Harmony Bioscience Are Falling on Friday

October 13, 2023 | fool.com

New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies

October 11, 2023 | markets.businessinsider.com

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

October 11, 2023 | finance.yahoo.com

H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)

October 10, 2023 | knoxdaily.com

Analysts: ZYNE stock price target of $1.25 in 12 months

October 5, 2023 | knoxdaily.com

Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions

October 4, 2023 | finance.yahoo.com

Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)

October 2, 2023 | knoxdaily.com

20 Countries With Highest Rate of Epilepsy

September 29, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023

September 29, 2023 | finance.yahoo.com

Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal

September 27, 2023 | bizjournals.com

Zynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Rise

September 25, 2023 | knoxdaily.com

Zynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwright

September 20, 2023 | knoxdaily.com

Negative sentiment towards ZYNE reflected in surge in short interest

September 15, 2023 | knoxdaily.com

Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Inc

September 14, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYNE, CRVS, IMMP, and TSVT Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

$3.62 -0.27 (-6.94%)

As of 04:00 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Immutep NASDAQ:IMMP

$1.83 -0.06 (-3.17%)

As of 04:00 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

2seventy bio NASDAQ:TSVT

$5.00 0.00 (0.00%)

As of 05/13/2025

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Zynerba Pharmaceuticals NASDAQ:ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time